A. Dekker

Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study

Ezra E.W. Cohen, Darren W. Davis, Theodore Karrison et al. · The Lancet Oncology · 2009 · 272 citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Ezra E.W. Cohen, Madeleine Kane, Marcy A. List et al. · Clinical Cancer Research · 2005 · 233 citations · Full text

Medicine, Oncology, Pharmacology +14

OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer

Tanguy Y. Seiwert, Corey C. Foster, Elizabeth A. Blair et al. · Annals of Oncology · 2018 · 233 citations · Full text

Medicine, Oncology, Radiation Oncology +14

Phase I Study of Bevacizumab Added to Fluorouracil- and Hydroxyurea-Based Concomitant Chemoradiotherapy for Poor-Prognosis Head and Neck Cancer

Tanguy Y. Seiwert, Daniel J. Haraf, Ezra E.W. Cohen et al. · Journal of Clinical Oncology · 2008 · 153 citations · Full text

Medicine, Oncology, Radiation Oncology +14

A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC)

Everett E. Vokes, Ezra E.W. Cohen, Ann M. Mauer et al. · Journal of Clinical Oncology · 2005 · 89 citations

Medicine, Oncology, Pharmacology +14